Prognostic impact of hepatitis C virus infection in patients with diffuse large B-cell lymphoma treated with immunochemotherapy in the context of a novel prognostic index

Cancer Epidemiology

Volumn 39, Issue 3, 2015, Pages 382-387

  Chen, Yi Yang ^a   Huang, Cih En ^a   Liang, Fu Wen ^b   Lu, Chang Hsien ^a,c   Chen, Pin Tsung ^a,c   Lee, Kuan Der ^a,c,d   Chen, Chih Cheng ^a,d  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Albumin; Diffuse large B cell lymphoma; Hepatitis C; NCCN IPI; Prognosis; Rituximab

Indexed keywords

ALBUMIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; SERUM ALBUMIN;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; LARGE CELL LYMPHOMA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NATIONAL COMPREHENSIVE CANCER NETWORK INTERNATIONAL PROGNOSTIC INDEX; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; AGED; COMPLICATION; HEPACIVIRUS; IMMUNOTHERAPY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; VIROLOGY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOTHERAPY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; SERUM ALBUMIN;

EID: 84929943737     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2015.04.004     Document Type: Article

References (39)

1. Ferri C., Caracciolo F., Zignego A.L., La Civita L., Monti M., Longombardo G., et al. Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. Br J Haematol 1994, 88(2):392-394.
2. Pozzato G., Mazzaro C., Crovatto M., Modolo M.L., Ceselli S., Mazzi G., et al. Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood 1994, 84(9):3047-3053.
3. Cox M.C., Aloe-Spiriti M.A., Cavalieri E., Alma E., Gigante E., Begini P., et al. HCV infection, B-cell non-Hodgkin's lymphoma and immunochemotherapy: evidence and open questions. World J Gastrointest Oncol 2012, 4(3):46-53.
4. Pioltelli P., Zehender G., Monti G., Monteverde A., Galli M. HCV and non-Hodgkin lymphoma. Lancet 1996, 347(9001):624-625.
5. Mele A., Pulsoni A., Bianco E., Musto P., Szklo A., Sanpaolo M.G., et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 2003, 102(3):996-999.
6. Peveling-Oberhag J., Arcaini L., Hansmann M.L., Zeuzem S. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol 2013, 59(1):169-177.
7. Visco C., Finotto S. Hepatitis C virus and diffuse large B-cell lymphoma: pathogenesis, behavior and treatment. World J Gastroenterol 2014, 20(32):11054-11061.
8. Nieters A., Kallinowski B., Brennan P., Ott M., Maynadie M., Benavente Y., et al. Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology 2006, 131(6):1879-1886.
9. de Sanjose S., Benavente Y., Vajdic C.M., Engels E.A., Morton L.M., Bracci P.M., et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008, 6(4):451-458.
10. Besson C., Canioni D., Lepage E., Pol S., Morel P., Lederlin P., et al. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol 2006, 24(6):953-960.
11. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New Engl J Med 2002, 346(4):235-242.
12. Pfreundschuh M., Trumper L., Osterborg A., Pettengell R., Trneny M., Imrie K., et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7(5):379-391.
13. Merli M., Visco C., Spina M., Luminari S., Ferretti V.V., Gotti M., et al. Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica 2014, 99(3):489-496.
14. Ennishi D., Maeda Y., Niitsu N., Kojima M., Izutsu K., Takizawa J., et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 2010, 116(24):5119-5125.
15. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. New Engl J Med 1993, 329(14):987-994.
16. Sehn L.H., Berry B., Chhanabhai M., Fitzgerald C., Gill K., Hoskins P., et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007, 109(5):1857-1861.
17. Zhou Z., Sehn L.H., Rademaker A.W., Gordon L.I., Lacasce A.S., Crosby-Thompson A., et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014, 123(6):837-842.
18. Mian M., Marcheselli L., Rossi A., Visco C., Chiappella A., Volpetti S., et al. A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma. Ann Oncol 2014.
19. Melchardt T., Troppan K., Weiss L., Hufnagl C., Neureiter D., Trankenschuh W., et al. A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and beta-microglobulin. Br J Haematol 2014.
20. Hans C.P., Weisenburger D.D., Greiner T.C., Gascoyne R.D., Delabie J., Ott G., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103(1):275-282.
21. Cheson B.D., Horning S.J., Coiffier B., Shipp M.A., Fisher R.I., Connors J.M., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999, 17(4):1244.
22. Feng J., Wang Z., Guo X., Chen Y., Cheng Y., Tang Y. Prognostic significance of absolute lymphocyte count at diagnosis of diffuse large B-cell lymphoma: a meta-analysis. Int J Hematol 2012, 95(2):143-148.
23. Hong J., Woo H.S., Kim H., Ahn H.K., Sym S.J., Park J., et al. Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy. Cancer Sci 2014.
24. Chen L.P., Lin S.J., Yu M.S. Prognostic value of platelet count in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk 2012, 12(1):32-37.
25. Tomita N., Kodama F., Takabayashi M., Kawano T., Yamaji S., Fujimaki K., et al. Clinical features and outcome in HCV-positive aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2003, 44(7):1159-1164.
26. Park B.B., Kim J.S., Lee Y.Y., Kang H.J., Ryoo B.Y., Kang J.H., et al. Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma. Leuk Lymphoma 2008, 49(1):88-94.
27. Visco C., Arcaini L., Brusamolino E., Burcheri S., Ambrosetti A., Merli M., et al. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol 2006, 17(9):1434-1440.
28. Pfreundschuh M., Schubert J., Ziepert M., Schmits R., Mohren M., Lengfelder E., et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008, 9(2):105-116.
29. Dalia S., Chavez J., Little B., Bello C., Fisher K., Lee J.H., et al. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. Ann Hematol 2014, 93(8):1305-1312.
30. Li X., Zhang Y., Zhao W., Liu Z., Shen Y., Li J., et al. The Glasgow Prognostic Score as a significant predictor of diffuse large B cell lymphoma treated with R-CHOP in China. Ann Hematol 2014.
31. Park S., Han B., Cho J.W., Woo S.Y., Kim S., Kim S.J., et al. Effect of nutritional status on survival outcome of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Nutr Cancer 2014, 66(2):225-233.
32. Ngo L., Hee S.W., Lim L.C., Tao M., Quek R., Yap S.P., et al. Prognostic factors in patients with diffuse large B cell lymphoma: before and after the introduction of rituximab. Leuk Lymphoma 2008, 49(3):462-469.
33. McMillan D.C., Watson W.S., O'Gorman P., Preston T., Scott H.R., McArdle C.S. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 2001, 39(2):210-213.
34. Gupta D., Lis C.G. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J 2010, 9:69.
35. Brenner D.A., Buck M., Feitelberg S.P., Chojkier M. Tumor necrosis factor-alpha inhibits albumin gene expression in a murine model of cachexia. J Clin Invest 1990, 85(1):248-255.
36. Marignani M., Mangone M., Cox M.C., Angeletti S., Veggia B., Ferrari A., et al. HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens. Digest Liver Dis 2011, 43(2):139-142.
37. Nishikawa H., Tsudo M., Osaki Y. Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience. Oncol Rep 2012, 28(3):835-840.
38. Salah-Eldin M.A., Ebrahim M.A., El-Sadda W. Clinical outcome of HCV-positive patients with diffuse large B-cell lymphoma treated with rituximab-based chemotherapy. Ann Hematol 2014, 93(11):1903-1911.
39. Augello C., Gianelli U., Savi F., Moro A., Bonoldi E., Gambacorta M., et al. MicroRNA as potential biomarker in HCV-associated diffuse large B-cell lymphoma. J Clin Pathol 2014, 67(8):697-701.